Nuvectis Pharma, Inc. (NASDAQ: NVCT) has priced its underwritten public offering of 5 million shares of common stock at $20.00 per share, expecting gross proceeds of approximately $100 million. The offering, announced in a press release, includes a 30-day option for underwriters to purchase up to an additional 750,000 shares at the same price, less underwriting discounts. The transaction is anticipated to close on or about July 1, 2026, subject to customary conditions.
The company intends to use the net proceeds to advance development of its key programs: NXP100, NXP200, and NXP900. These funds will also support future product candidates, hiring additional personnel, capital expenditures, and general corporate purposes. Cantor is acting as sole book-running manager, with co-managers including H.C. Wainwright & Co., Laidlaw & Company (UK) Ltd., Lucid Capital Markets, Maxim Group LLC, Roth Capital Partners, and Titan Partners.
Nuvectis Pharma is a clinical-stage biopharmaceutical company focused on innovative therapies for immune complement-related conditions and oncology. Its pipeline includes NXP100, a late-stage complement Factor B inhibitor with best-in-class potential as an effective once-daily oral treatment for multiple complement-mediated diseases requiring lifelong therapy. NXP900 is an oral small molecule inhibitor targeting the SRC Family of Kinases, including SRC and YES1, designed to inhibit both catalytic and scaffolding functions for comprehensive signaling pathway shutdown. NXP200 is an oral, brain-penetrant, paradox-breaker BRAF inhibitor for BRAF V600X-mutated and Class II/III non-V600-mutated solid tumors, including central nervous system cancer, colorectal cancer, melanoma, and non-small cell lung cancer, with best-in-class potential.
This capital raise is significant for the biopharmaceutical industry as it enables Nuvectis to accelerate clinical development of its pipeline, potentially bringing novel therapies to patients with high unmet medical needs. The funding could advance NXP100 as a convenient oral option for complement-mediated diseases, addressing a market currently dominated by injectable therapies. For oncology, NXP900 and NXP200 target critical pathways in cancer progression and resistance, offering new treatment avenues for patients with limited options. The participation of multiple underwriters underscores investor confidence in Nuvectis' strategy.
The impact on the industry includes potential shifts in treatment paradigms for complement-mediated diseases and BRAF-mutated cancers. If successful, these programs could reduce the burden of lifelong injectable treatments and provide effective therapies for hard-to-treat tumors. For leaders in business and technology, this news highlights the ongoing convergence of biotechnology and investment, where strategic capital allocation drives innovation. The offering also reflects the broader trend of biopharmaceutical companies raising funds to advance precision medicine and targeted therapies.
For more information, visit the company's website at https://nuvectis.com/.
